---
layout: default
title: Hydroxyurea
description: "Hydroxyurea çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚é«˜è­‰æ“šç­‰ç´š L2ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: é«˜è­‰æ“šç­‰ç´š (L1-L2)
nav_order: 83
evidence_level: L1
indication_count: 10
---

# Hydroxyurea

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L2</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Hydroxyureaï¼šå¾è¡€æ¶²è…«ç˜¤åˆ°å¥³æ€§ä¹³è…ºç™Œ

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Hydroxyurea å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Hydroxyurea åŸæœ¬ç”¨æ–¼æ²»ç™‚æ…¢æ€§éª¨é«“æ€§ç™½è¡€ç—…ã€éª¨é«“çº–ç¶­åŒ–åŠçœŸæ€§ç´…è¡€çƒå¢å¤šç—‡ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**å¥³æ€§ä¹³è…ºç™Œ (female breast carcinoma)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **è¶…é 20 ç¯‡æ–‡ç»**æ”¯æŒé€™å€‹ç ”ç©¶æ–¹å‘ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | æ…¢æ€§éª¨é«“æ€§ç™½è¡€ç—…ã€éª¨é«“çº–ç¶­åŒ–ã€çœŸæ€§ç´…è¡€çƒå¢å¤šç—‡ã€åµå·¢ç™Œã€é ­é ¸ç™Œ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | å¥³æ€§ä¹³è…ºç™Œã€primary non-gestational choriocarcinoma of ovaryã€sickle cell-hemoglobin E disease syndromeã€sickle cell-hemoglobin c disease syndromeã€hereditary persistence of fetal hemoglobin-sickle cell disease syndromeã€sickle cell-hemoglobin d disease syndromeã€sickle cell-beta-thalassemia disease syndromeã€hereditary breast ovarian cancer syndromeã€ovarian mucinous adenocarcinomaã€ovarian clear cell adenocarcinoma |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.97% |
| è­‰æ“šç­‰ç´š | L2 |
| å°ç£ä¸Šå¸‚ | æœ‰æ•ˆè¨±å¯è­‰ |
| è¨±å¯è­‰æ•¸ | å¤šå¼µ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |



## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. female breast carcinoma</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.97%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>Hydroxyurea æ˜¯ä¸€ç¨®æ ¸ç³–æ ¸è‹·é…¸é‚„åŸé…¶æŠ‘åˆ¶åŠ‘ï¼Œé€éé˜»æ–· DNA åˆæˆç™¼æ®æŠ—è…«ç˜¤ä½œç”¨ã€‚</p>
<p>å®ƒå¯ä»¥æŠ‘åˆ¶ç´°èƒå¾ G1 æœŸé€²å…¥ S æœŸï¼Œä¸¦å¢åŠ ç´°èƒå°æ”¾å°„ç·šçš„æ•æ„Ÿæ€§ã€‚</p>

<p><strong>é æ¸¬åˆç†æ€§åˆ†æï¼š</strong></p>
<ul>
<li>Hydroxyurea å·²æ ¸å‡†ç”¨æ–¼å¤šç¨®å¯¦é«”è…«ç˜¤ï¼ˆåµå·¢ç™Œã€é ­é ¸ç™Œï¼‰</li>
<li>åœ¨ä¹³ç™Œçš„é«˜åŠ‘é‡åŒ–ç™‚æ–¹æ¡ˆä¸­å·²æœ‰ä½¿ç”¨ç¶“é©—</li>
<li>å¯ä½œç‚ºæ”¾å°„å¢æ•åŠ‘ï¼Œèˆ‡æ”¾å°„æ²»ç™‚åˆä½µä½¿ç”¨</li>
<li>ç ”ç©¶é¡¯ç¤ºå¯èˆ‡å…¶ä»–è—¥ç‰©ï¼ˆå¦‚ valproic acidï¼‰ç”¢ç”Ÿå”åŒä½œç”¨</li>

</ul>
<p><strong>æ©Ÿè½‰æ”¯æŒï¼š</strong></p>
<ul>
<li>æŠ‘åˆ¶ DNA åˆæˆå’Œä¿®å¾©</li>
<li>èª˜å°è¤‡è£½å£“åŠ›ï¼Œå¢åŠ  DNA é›™è‚¡æ–·è£‚</li>
<li>èˆ‡ valproic acid åˆä½µå¯æŠ‘åˆ¶åŒæºé‡çµ„ä¿®å¾©ï¼ˆPMID: 28837865ï¼‰</li>
<li>è„‚è³ªè—¥ç‰©è¤‡åˆé«”å¯æé«˜ç´°èƒæ”å–ç‡ï¼ˆPMID: 38211596ï¼‰</li>
</ul>

<h3>è‡¨åºŠè©¦é©—</h3>

<p>æ–‡ç»ä¸­å ±å‘Šçš„è‡¨åºŠç¶“é©—åŒ…æ‹¬ï¼š</p>

<table>
<thead>
<tr>
<th>ç ”ç©¶é¡å‹</th>
<th>å¹´ä»½</th>
<th>æœŸåˆŠ</th>
<th>ä¸»è¦ç™¼ç¾</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase I</td>
<td>1991</td>
<td>Am J Clin Oncol</td>
<td>FU-LV-HU çµ„åˆæ–¹æ¡ˆåœ¨æ™šæœŸä¹³ç™Œä¸­çš„ Phase I è©¦é©—</td>
</tr>
<tr>
<td>Phase I/II</td>
<td>1994</td>
<td>Bone Marrow Transplant</td>
<td>é«˜åŠ‘é‡ CY-Thiotepa-HU é…åˆè‡ªé«”å¹¹ç´°èƒç§»æ¤ç”¨æ–¼è½‰ç§»æ€§ä¹³ç™Œ</td>
</tr>
<tr>
<td>Phase I</td>
<td>1992</td>
<td>Cancer Chemother Pharmacol</td>
<td>5-FUã€LVã€HU èˆ‡ cisplatin åˆä½µæ”¾ç™‚çš„è‡¨åºŠè—¥ç†å­¸ç ”ç©¶</td>
</tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»</h3>

<table>
<thead>
<tr>
<th>PMID</th>
<th>å¹´ä»½</th>
<th>é¡å‹</th>
<th>æœŸåˆŠ</th>
<th>ä¸»è¦ç™¼ç¾</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/38211596/">38211596</a></td>
<td>2024</td>
<td>é›»è…¦æ¨¡æ“¬</td>
<td>Drug Res</td>
<td>HU è„‚è³ªè—¥ç‰©è¤‡åˆé«”è¨­è¨ˆï¼Œé¶å‘ PI3K/AKT/mTOR é€šè·¯</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/28837865/">28837865</a></td>
<td>2017</td>
<td>é«”å¤–ç ”ç©¶</td>
<td>DNA Repair</td>
<td>Valproic acid å¢æ•ä¹³ç™Œç´°èƒå° HU çš„åæ‡‰</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/32795962/">32795962</a></td>
<td>2020</td>
<td>é«”å¤–ç ”ç©¶</td>
<td>DNA Repair</td>
<td>2-hexyl-4-pentynoic acid èˆ‡ HU è¯åˆæŠ‘åˆ¶ä¹³ç™Œ</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/7914447/">7914447</a></td>
<td>1994</td>
<td>Phase I/II</td>
<td>Bone Marrow Transplant</td>
<td>é«˜åŠ‘é‡ CY-Thiotepa-HU ç”¨æ–¼è½‰ç§»æ€§ä¹³ç™Œçš„éå›ºæ²»ç™‚</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/21730979/">21730979</a></td>
<td>2011</td>
<td>é«”å¤–ç ”ç©¶</td>
<td>Br J Cancer</td>
<td>ATR æŠ‘åˆ¶åŠ‘èˆ‡ HU åœ¨ä¹³ç™Œå’Œåµå·¢ç™Œç´°èƒä¸­çš„æ•ˆæœ</td>
</tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. sickle cell-hemoglobin E disease syndrome</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.67%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ4 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03763656" target="_blank">NCT03763656</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>33</td><td>A Prospective Open Label, Pharmacokinetic Study of an Oral Hydroxyurea Solution ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03264989" target="_blank">NCT03264989</a></td><td>PHASE2</td><td>COMPLETED</td><td>57</td><td>A Phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (Crizanlizuma...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02709681" target="_blank">NCT02709681</a></td><td>N/A</td><td>COMPLETED</td><td>628</td><td>Hydroxyurea in Sickle Cell Disease: a Large Nation-wide Cohort Study From Italy</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04927247" target="_blank">NCT04927247</a></td><td>PHASE3</td><td>TERMINATED</td><td>72</td><td>A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Do...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ1 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36799926/" target="_blank">36799926</a></td><td>2023</td><td>Article</td><td>Blood advances</td><td>Most adults with severe HbSC disease are not treated with hy...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. sickle cell-hemoglobin c disease syndrome</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.67%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ11 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03975894" target="_blank">NCT03975894</a></td><td>PHASE2</td><td>UNKNOWN</td><td>50</td><td>A Feasibility Trial of Serial Prophylactic Exchange Blood Transfusion in Pregnan...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01987908" target="_blank">NCT01987908</a></td><td>PHASE2</td><td>TERMINATED</td><td>35</td><td>A Phase 2, Exploratory, Placebo-Controlled, Multicenter, Double-Blind Evaluation...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02640573" target="_blank">NCT02640573</a></td><td>PHASE2</td><td>TERMINATED</td><td>1</td><td>Treatment of Adult Patients With Hemoglobin SC Disease</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03474965" target="_blank">NCT03474965</a></td><td>PHASE2</td><td>COMPLETED</td><td>117</td><td>A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evalu...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05850156" target="_blank">NCT05850156</a></td><td>N/A</td><td>NOT_YET_RECRUITING</td><td>130</td><td>Study of a Deformability Parameter of Red Blood Cell. FITRED</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 6 é …è©¦é©—</em></p>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ19 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36047926/" target="_blank">36047926</a></td><td>2022</td><td>Article</td><td>The Cochrane databas</td><td>Hydroxyurea (hydroxycarbamide) for sickle cell disease.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39647172/" target="_blank">39647172</a></td><td>2025</td><td>Article</td><td>NEJM evidence</td><td>Hydroxyurea for Children and Adults with Hemoglobin SC Disea...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28426137/" target="_blank">28426137</a></td><td>2017</td><td>Article</td><td>The Cochrane databas</td><td>Hydroxyurea (hydroxycarbamide) for sickle cell disease.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33679049/" target="_blank">33679049</a></td><td>2021</td><td>Article</td><td>Journal of clinical </td><td>Sickle Hepatopathy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11406036/" target="_blank">11406036</a></td><td>2001</td><td>Article</td><td>The Cochrane databas</td><td>Hydroxyurea for sickle cell disease.</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 14 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. hereditary persistence of fetal hemoglobin-sickle cell disease syndrome</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.67%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ1 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23342821/" target="_blank">23342821</a></td><td>2012</td><td>Article</td><td>Journal of the Natio</td><td>Kikuchi-Fugimoto&#x27;s disease in sickle cell disease: report of...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. sickle cell-hemoglobin d disease syndrome</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.67%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ4 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04046705" target="_blank">NCT04046705</a></td><td>PHASE3</td><td>UNKNOWN</td><td>78</td><td>A Prospective Multicenter Trial Comparing Allogeneic Matched Related Haematopoie...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06464458" target="_blank">NCT06464458</a></td><td>NA</td><td>RECRUITING</td><td>30</td><td>Optimizing the Management of Sickle Cell Patients on Hydroxyurea: The Value of T...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03763656" target="_blank">NCT03763656</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>33</td><td>A Prospective Open Label, Pharmacokinetic Study of an Oral Hydroxyurea Solution ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06979492" target="_blank">NCT06979492</a></td><td>PHASE4</td><td>NOT_YET_RECRUITING</td><td>50</td><td>Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ2 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36799926/" target="_blank">36799926</a></td><td>2023</td><td>Article</td><td>Blood advances</td><td>Most adults with severe HbSC disease are not treated with hy...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20502357/" target="_blank">20502357</a></td><td>2010</td><td>Article</td><td>Journal of pediatric</td><td>First report of successful stem cell transplantation in a pa...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. sickle cell-beta-thalassemia disease syndrome</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.67%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ4 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01962415" target="_blank">NCT01962415</a></td><td>PHASE2</td><td>RECRUITING</td><td>100</td><td>A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and You...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04528355" target="_blank">NCT04528355</a></td><td>N/A</td><td>RECRUITING</td><td>50</td><td>A Prospective Outcomes Study of Pediatric and Adult Patients With Non-Malignant ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03653338" target="_blank">NCT03653338</a></td><td>PHASE1, PHASE2</td><td>RECRUITING</td><td>5</td><td>T-Cell Depleted, Alternative Donor Transplant in Pediatric and Adult Patients Wi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03763656" target="_blank">NCT03763656</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>33</td><td>A Prospective Open Label, Pharmacokinetic Study of an Oral Hydroxyurea Solution ...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ2 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27053181/" target="_blank">27053181</a></td><td>2016</td><td>Article</td><td>Indian journal of pe</td><td>Sickle Cell Disease in Central India: A Potentially Severe S...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/10326220/" target="_blank">10326220</a></td><td>1999</td><td>Article</td><td>Pediatric hematology</td><td>Effect of hydroxyurea in sickle cell anemia: a clinical tria...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. cervical adenosarcoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.40%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. colon mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.32%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. rectum mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.31%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. gallbladder mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.28%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| - | æ·å¯è¡›éŒ  | éŒ åŠ‘ | éª¨é«“çº–ç¶­åŒ–ã€çœŸæ€§ç´…è¡€çƒå¢å¤šç—‡ã€GvHD |
| - | Hydroxyurea è† å›Š | è† å›Š | æ…¢æ€§éª¨é«“æ€§ç™½è¡€ç—…ã€åµå·¢ç™Œã€é ­é ¸ç™Œ |

## å®‰å…¨æ€§è€ƒé‡

- **è—¥ç‰©äº¤äº’ä½œç”¨**ï¼šæ–‡ç»ä¸­å¤šèˆ‡å…¶ä»–åŒ–ç™‚è—¥ç‰©åˆä½µä½¿ç”¨
- **æ³¨æ„äº‹é …**ï¼š
  - éª¨é«“æŠ‘åˆ¶æ˜¯æœ€ä¸»è¦çš„åŠ‘é‡é™åˆ¶æ¯’æ€§
  - é•·æœŸä½¿ç”¨å¯èƒ½å¢åŠ ç¹¼ç™¼æ€§ç™½è¡€ç—…é¢¨éšª
  - çš®è†šæ¯’æ€§ï¼ˆè‰²ç´ æ²‰è‘—ã€æ½°ç˜ï¼‰
  - å·¨çƒæ€§è²§è¡€
- **ä¹³ç™Œé©ç”¨è€ƒé‡**ï¼š
  - ç›®å‰å¤šç”¨æ–¼é«˜åŠ‘é‡åŒ–ç™‚æ–¹æ¡ˆ
  - éœ€è€ƒé‡èˆ‡ç¾æœ‰æ¨™æº–æ²»ç™‚çš„æ¯”è¼ƒ

å®‰å…¨æ€§è³‡è¨Šè«‹åƒè€ƒåŸå» ä»¿å–®ã€‚


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Nervous System Diseases** ğŸ”´ Major
- æ³¨æ„äº‹é …ï¼šNeurological symptoms such as disorientation or hallucinations have been reported very rarely during hydroxyurea therapy...

**è‚è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½éœ€è¦èª¿æ•´åŠ‘é‡ã€‚

**ç™²ç™‡** ğŸŸ¡ Moderate
- é¢¨éšªåŒ…æ‹¬ï¼šç™²ç™‡ç™¼ä½œã€‚

**Bone Marrow Failure Disorders** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šéª¨é«“æŠ‘åˆ¶ã€å‡ºè¡€ã€æ„ŸæŸ“ã€è¡€æ “ã€è²§è¡€ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**è…è‡Ÿç–¾ç—…** ğŸŸ¢ Minor
- æ³¨æ„äº‹é …ï¼šHydroxyurea is primarily eliminated by the kidney...

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
- è±å¯Œçš„é«”å¤–ç ”ç©¶æ”¯æŒ HU åœ¨ä¹³ç™Œä¸­çš„æ´»æ€§
- å·²æœ‰ Phase I/II è‡¨åºŠç¶“é©—ï¼Œå°¤å…¶åœ¨é«˜åŠ‘é‡åŒ–ç™‚æ–¹æ¡ˆä¸­
- æ–°ç©çš„è—¥ç‰©å‚³éç³»çµ±ï¼ˆå¦‚è„‚è³ªè¤‡åˆé«”ï¼‰å¯èƒ½æ”¹å–„ç™‚æ•ˆ
- èˆ‡å…¶ä»–è—¥ç‰©çš„å”åŒä½œç”¨æä¾›è¯åˆæ²»ç™‚æ©Ÿæœƒ

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- è©•ä¼° HU åœ¨ç¾ä»£ä¹³ç™Œæ²»ç™‚ä¸­çš„è§’è‰²ï¼ˆèˆ‡ CDK4/6 æŠ‘åˆ¶åŠ‘ã€å…ç–«æ²»ç™‚çš„æ¯”è¼ƒæˆ–è¯åˆï¼‰
- é–‹ç™¼æ›´æœ‰æ•ˆçš„è—¥ç‰©å‚³éç³»çµ±ä»¥æé«˜è…«ç˜¤é¶å‘æ€§
- ç¢ºå®šæœ€é©åˆçš„ä¹³ç™Œäºå‹ï¼ˆå¦‚ä¸‰é™°æ€§ä¹³ç™Œï¼‰
- è¨­è¨ˆèˆ‡ valproic acid æˆ–å…¶ä»–å¢æ•åŠ‘çš„è¯åˆç”¨è—¥æ–¹æ¡ˆ

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Acetazolamide]({{ "/drugs/acetazolamide/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Vonoprazan]({{ "/drugs/vonoprazan/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Omalizumab]({{ "/drugs/omalizumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Gemcitabine]({{ "/drugs/gemcitabine/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Prednisone]({{ "/drugs/prednisone/" | relative_url }}) - è­‰æ“šç­‰ç´š L2

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Hydroxyureaè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/hydroxyurea/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_hydroxyurea,
  title = {Hydroxyureaè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/hydroxyurea/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
